ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
10.08
-0.17 (-1.66%)
At close: May 6, 2026, 4:00 PM EDT
7.70
-2.38 (-23.61%)
After-hours: May 6, 2026, 7:59 PM EDT
ADMA Biologics Stock Forecast
Stock Price Forecast
The 3 analysts that cover ADMA Biologics stock have a consensus rating of "Strong Buy" and an average price target of $25.67, which forecasts a 154.66% increase in the stock price over the next year. The lowest target is $21 and the highest is $32.
Price Target: $25.67 (+154.66%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ADMA Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 1 | 2 | 2 |
| Buy | 1 | 1 | 1 | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 2 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $21 | Strong Buy | Initiates | $21 | +108.33% | Apr 21, 2026 |
| Mizuho | Mizuho | Buy Maintains $30 → $24 | Buy | Maintains | $30 → $24 | +138.10% | Apr 13, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 26, 2026 |
| Raymond James | Raymond James | Strong Buy Maintains $25 → $32 | Strong Buy | Maintains | $25 → $32 | +217.46% | May 8, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $25 | Buy | Reiterates | $25 | +148.02% | Mar 4, 2025 |
Financial Forecast
Revenue This Year
645.01M
from 510.17M
Increased by 26.43%
Revenue Next Year
788.02M
from 645.01M
Increased by 22.17%
EPS This Year
0.99
from 0.60
Increased by 65.47%
EPS Next Year
1.28
from 0.99
Increased by 28.43%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 672.0M | 820.5M | ||||||
| Avg | 645.0M | 788.0M | ||||||
| Low | 609.7M | 745.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 31.7% | 27.2% | ||||||
| Avg | 26.4% | 22.2% | ||||||
| Low | 19.5% | 15.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 1.09 | 1.45 | |||||
| Avg | 0.99 | 1.28 | |||||
| Low | 0.85 | 1.08 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 82.0% | 46.0% | |||||
| Avg | 65.5% | 28.4% | |||||
| Low | 42.1% | 8.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.